Brief: CGBio's 'Novosis Putty' Receives FDA 'Breakthrough Device Designation'
02/01/2024 14:26
Jan 2 (Reuters) - CGBio:
* CGBIO - EXPECTS TO RECEIVE FASTER APPROVAL IN U.S. BY
PRIORITY
SUPPORT FROM FDA
* CGBIO'S 'NOVOSIS PUTTY' RECEIVES FDA 'BREAKTHROUGH DEVICE
DESIGNATION,' ACCELERATE ENTRY INTO THE US MARKET
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier